PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

CARDIOVALVE LTD.

USPTO PatentsView assignee record — 119 granted patents across 16 technology areas, active 2018–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).

Explore the portfolio See the ranking
119
Total patents granted
16
CPC technology areas
21.4
Avg claims per patent
+426%
5-year filing velocity

The verdict

CARDIOVALVE holds 119 US patents across 16 technology areas — rank #3,153 of 50,000 tracked assignees.

#3,153
of 50,000 US assignees by volume
Top 14%
by Innovation Score (50.0/100)
21.4
avg claims per patent
+426%
filing velocity, last 5 yrs

Portfolio overview

CARDIOVALVE LTD. has been granted 119 US utility patents between 2018 and 2025, placing CARDIOVALVE LTD. at rank #3,153 across all assignees tracked by PlainPatent. This portfolio spans 16 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.4 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a Foreign Corporation, CARDIOVALVE LTD. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 50.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 100 grants, compared with 19 in the 2015–2019 window — a +426% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. CARDIOVALVE LTD.'s 21.4 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 16 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark CARDIOVALVE LTD. against peers pursuing similar technology classes.

How does CARDIOVALVE compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows CARDIOVALVE holds 119 patents — placing it at rank #3,153 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

CARDIOVALVE's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

50 Top 14% higher than 86% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). This entry sits in this band. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

0102030 20182019202020212022202320242025 6
USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table
CARDIOVALVE LTD. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2018 2 1.7%
2019 17 14.3%
2020 25 21.0%
2021 14 11.8%
2022 22 18.5%
2023 15 12.6%
2024 18 15.1%
2025 6 5.0%

Which technologies does CARDIOVALVE LTD. patent most?

Top 15 of 16 technology areas

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Focused
Claim Depth Complex
Velocity Accelerating

Where it ranks

Overall rank by patents

#3,153

Across all tracked assignees

Innovation Score

50.0 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does CARDIOVALVE LTD. hold?
CARDIOVALVE LTD. holds 119 US granted patents filed between 2018 and 2025, spanning 16 technology areas.
What is CARDIOVALVE LTD.'s Innovation Score?
CARDIOVALVE LTD. has an Innovation Score of 50.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does CARDIOVALVE LTD. focus on?
CARDIOVALVE LTD.'s top technology area is A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS) with 117 patents. The company has filed patents in 16 CPC subclasses total.
Is CARDIOVALVE LTD.'s patent filing rate increasing or decreasing?
CARDIOVALVE LTD.'s recent filing velocity is +426% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for CARDIOVALVE LTD.'s patents?
CARDIOVALVE LTD.'s patents average 21.4 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the CARDIOVALVE LTD. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How Innovation Score Works

Understand the four dimensions behind the composite score
How to Read Patent Data

Plain-English guide to CPC codes, claims, and metrics
Patent Moat Analysis

How companies use patents as competitive barriers

Explore the patent dataset

A61F technology

CARDIOVALVE LTD.'s primary CPC class — all holders and yearly trends
Top 50 patent holders

See where CARDIOVALVE LTD. ranks among the largest US patent assignees
All technology classes

Browse every CPC technology area by patent activity
How the score works

The four dimensions behind the Innovation Score

Related

All companies → | All technologies → | Rankings →
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology — how this data is sourced, computed, and verified.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope